Skip to main content

Advertisement

SpringerLink
Log in

Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy

  • Research Article
  • Published:
Tumor Biology

Abstract

Polymorphisms in the excision repair cross-complimentary group 1 (ERCC1)–excision repair cross-complimentary group 4 (ERCC4) genes have been implicated in the prognosis of various cancers. We conducted a cohort study to investigate the role of ERCC1–ERCC4 gene polymorphisms on the response to chemotherapy and the role of these two gene polymorphisms on the clinical outcomes of gastric cancer. Four hundred forty-seven patients with newly diagnosed and histopathologically confirmed primary gastric cancer were collected in our study and were followed up until March 2012. ERCC1 (rs11615, rs3212986C>A, and rs2298881) and ERCC4 (rs226466C>G, rs2276465, and rs6498486) were selected and genotyped. The overall chemotherapy response rate for treatment was 68 %. Carriers of the rs11615 TT and T allele and ERCC1 rs2298881 CC and C allele had a marginally significantly higher response rate to the chemotherapy. In the Cox proportional hazard model, the hazard ratios (HRs) for overall survival (OS) in patients carrying ERCC1 rs11615 TT genotype and T allele were 0.53 (0.29–0.95) and 0.63 (0.42–0.94), respectively. Similarly, we found a significant decreased risk of death from gastric cancer among patients carrying ERCC1 rs2298881 CC genotype and C allele when compared with CC genotype, and HRs (95 % confidence interval (CI)) of OS were 0.50 (0.24–0.98) and 0.62 (0.40–0.96), respectively. Moreover, individuals carrying ERCC1 rs11615 T allele and rs2298881 C allele could decrease a 0.62-fold risk of death from gastric cancer. This study reported a carriage of ERCC1 rs11615, and rs2298881 polymorphism can be used as a predictor of response to folinic acid/5-fluorouracil (5-FU)/oxaliplatin (FOLFOX)-based chemotherapy in gastric cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. International Agency for Research on Cancer. Globocan 2008: stomach cancer incidence, mortality and prevalence worldwide in 2008. IARC. 2008

  2. Macdonald JS. Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol. 2004;54:S4–S11.

    PubMed  CAS  Google Scholar 

  3. Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol. 2004;15:1585–95.

    Article  PubMed  CAS  Google Scholar 

  4. Pasini F, Fraccon AP, DEM G. The role of chemotherapy in metastatic gastric cancer. Anticancer Res. 2011;31(10):3543–54.

    PubMed  CAS  Google Scholar 

  5. Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol. 2007;46:336–41.

    Article  PubMed  CAS  Google Scholar 

  6. Kim YS, Hong J, Sym SJ, et al. Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer. Cancer Res Treat. 2010;42:24–9.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science. 2001;291:1284–9.

    Article  PubMed  CAS  Google Scholar 

  8. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol. 2000;20:7980–90.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1:22–33.

    Article  PubMed  CAS  Google Scholar 

  10. Cleaver JE. Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum. J Dermatol Sci. 2000;23:1–11.

    Article  PubMed  CAS  Google Scholar 

  11. Mu D, Hsu DS, Sancar A. Reaction mechanism of human DNA repair excision nuclease. J Biol Chem. 1996;271:8285–94.

    Article  PubMed  CAS  Google Scholar 

  12. Sancar A. Mechanisms of DNA excision repair. Science. 1994;266:1954–68.

    Article  PubMed  CAS  Google Scholar 

  13. Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry. 1996;35:10004–13.

    Article  PubMed  CAS  Google Scholar 

  14. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2001;2:483–90.

    Article  PubMed  CAS  Google Scholar 

  15. Deloia JA, Bhagwat NR, Darcy KM, Strange M, Tian C, Nuttall K, et al. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. Gynecol Oncol. 2012;126:448–54.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  16. Fareed KR, Al-Attar A, Soomro IN, Kaye PV, Patel J, Lobo DN, et al. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer. 2010;102:1600–7.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  17. Vaezi A, Wang X, Buch S, Gooding W, Wang L, Seethala RR, et al. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2011;1:5513–22. 2011.

    Article  CAS  Google Scholar 

  18. Alexander BM, Sprott K, Farrow DA, Wang X, D’Andrea AD, Schnitt SJ, et al. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin Cancer Res. 2010;16:5796–804.

    Article  PubMed  CAS  Google Scholar 

  19. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.

    Article  PubMed  CAS  Google Scholar 

  20. Yang Z, Fang X, Pei X, Li H. Polymorphisms in the ERCC1 and XPF genes and risk of breast cancer in a Chinese population. Genet Test Mol Biomark. 2013;17:700–6.

    Article  CAS  Google Scholar 

  21. Mohseni-Meybodi A, Mozdarani H, Mozdarani S. DNA damage and repair of leukocytes from Fanconi anaemia patients, carriers and healthy individuals as measured by the alkaline comet assay. Mutagenesis. 2009;24(1):67–73.

    Article  PubMed  CAS  Google Scholar 

  22. Knipscheer P, Raschle M, Smogorzewska A, Enoiu M, Ho TV, Scharer OD, et al. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science. 2009;326:1698–701.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  23. Liu T, Ghosal G, Yuan J, Chen J, Huang J. FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair. Science. 2010;329:693–6.

    Article  PubMed  CAS  Google Scholar 

  24. Xu TP, Shen H, Liu LX, Shu YQ. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene. 2013;526:265–74.

    Article  PubMed  CAS  Google Scholar 

  25. Chen C, Wang F, Wang Z, Li C, Luo H, Liang Y, et al. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2013;72:315–22.

    Article  PubMed  CAS  Google Scholar 

  26. Gerhard R, Carvalho A, Carneiro V, Bento RS, Uemura G, Gomes M, et al. Clinicopathological significance of ERCC1 expression in breast cancer. Pathol Res Pract. 2013;209(6):331–6.

    Article  PubMed  CAS  Google Scholar 

  27. Chu H, Gu D, Xu M, Xu Z, Gong Y, Gong W, et al. A genetic variant in ERCC2 is associated with gastric cancer prognosis in a Chinese population. Mutagenesis. 2013;28(4):441–6.

    Article  PubMed  CAS  Google Scholar 

  28. He SY, Xu L, Niu G, Ke PQ, Feng MM, Shen HW. Predictive value of excision repair cross-complementing rodent repair deficiency complementation group 1 and ovarian cancer risk. Asian Pac J Cancer Prev. 2012;13:1799–802.

    Article  PubMed  Google Scholar 

  29. Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y. Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterol. 2012;12:137.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  30. Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, et al. The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Oncol Lett. 2013;5(3):935–42.

    PubMed Central  PubMed  CAS  Google Scholar 

  31. Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, et al. Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Mol Med Rep. 2013;7(6):1904–11.

    PubMed  CAS  Google Scholar 

  32. Gustavsson B, Kaiser C, Carlsson G, Wettergren Y, Odin E, Lindskog EB, et al. Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. Int J Cancer. 2009;124:1220–6.

    Article  PubMed  CAS  Google Scholar 

  33. Liang J, Li QF, Yao RY, Lü HY, Jiang J, Sun YY, et al. Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy. Zhonghua Zhong Liu Za Zhi. 2010;32:515–9.

    PubMed  CAS  Google Scholar 

  34. Goode EL, Ulrich MC, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomark Prev. 2002;11:1513–30.

    CAS  Google Scholar 

  35. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998;24:331–44.

    Article  PubMed  CAS  Google Scholar 

  36. He J, Xu Y, Qiu LX, Li J, Zhou XY, Sun MH, et al. Polymorphisms in ERCC1 and XPF genes and risk of gastric cancer in an eastern Chinese population. PLoS One. 2012;7:e49308.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  37. Palli D, Polidoro S, D’Errico M, Saieva C, Guarrera S, Calcagnile AS, et al. Polymorphic DNA repair and metabolic genes: a multigenic study on gastric cancer. Mutagenesis. 2010;25:569–75.

    Article  PubMed  CAS  Google Scholar 

  38. Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, et al. Bio-FAST trial group: ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer. 2013;108:1695–703.

    Article  PubMed  CAS  Google Scholar 

  39. Arienti C, Tesei A, Verdecchia GM, Framarini M, Virzì S, Grassi A, et al. Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. Clin Colorectal Cancer. 2013;12:122–7.

    Article  PubMed  CAS  Google Scholar 

  40. Yang LM, Li XH, Bao CF. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors. Asian Pac J Cancer Prev. 2012;13:5883–6.

    Article  PubMed  Google Scholar 

  41. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res. 2011;17:1632–40.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  42. Barry KH, Koutros S, Andreotti G, Sandler DP, Burdette LA, Yeager M, et al. Genetic variation in nucleotide excision repair pathway genes, pesticide exposure and prostate cancer risk. Carcinogenesis. 2012;33:331–7.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  43. Zhu XD, Niedernhofer L, Kuster B, Mann M, Hoeijmakers JH, de Lange T. ERCC1/XPF removes the 3′ overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol Cell. 2003;12:1489–98.

    Article  PubMed  CAS  Google Scholar 

  44. Kornguth DG, Garden AS, Zheng Y, Dahlstrom KR, Wei Q, Sturgis EM. Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. Int J Radiat Oncol Biol Phys. 2005;62:665–71.

    Article  PubMed  Google Scholar 

  45. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, et al. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer. 2008;98:832–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  46. Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer. 2008;8:97.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  47. Ozkan M, Akbudak IH, Deniz K, Dikilitas M, Dogu GG, Berk V, et al. Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. Asian Pac J Cancer Prev. 2010;11:181–5.

    PubMed  Google Scholar 

  48. Yun J, Kim KM, Kim ST, Kim JH, Kim JA, Kong JH, et al. Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy. Cancer Res Treat. 2010;42:101–6.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Yin J, Vogel U, Ma Y, Qi R, Wang H, Yue L, et al. HapMap-based study of a region encompassing ERCC1 and ERCC2 related to lung cancer susceptibility in a Chinese population. Mutat Res. 2011;713:1–7.

    Article  PubMed  CAS  Google Scholar 

  50. Alexander BM, Wang XZ, Niemierko A, Weaver DT, Mak RH, Roof KS, et al. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;83:164–71.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the funding of “1255” scientific innovation project (CH125542800) and National Scientific Fund (81101418/H1504).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of General Surgery, Changhai Hospital, The Second Military Medical University, Shanghai, 200433, People’s Republic of China

    Zheng-mao Lu, Tian-hang Luo, Ming-ming Nie, Guo-en Fang, Li-ye Ma, Xu-chao Xue, Guo Wei, Chong-we Ke & Jian-wei Bi

Authors
  1. Zheng-mao Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tian-hang Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ming-ming Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guo-en Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li-ye Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xu-chao Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guo Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chong-we Ke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jian-wei Bi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian-wei Bi.

Additional information

Zheng-mao Lu and Tian-hang Luo contributed equally to our study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lu, Zm., Luo, Th., Nie, Mm. et al. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy. Tumor Biol. 35, 2941–2948 (2014). https://doi.org/10.1007/s13277-013-1378-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1378-7

Keywords

Search

Navigation